Divis Laboratories logo

Divis Laboratories

DIVISLAB NSE

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
2.5L Cr
Volatility
Moderate
P/E Ratio
84.61
EBITDA
₹3,948 Cr
Return on Equity
15.32%
Debt to Equity
0
Book Value
₹631.38
EPS
₹63.06
52W High
₹9,615
52W Low
₹5,636.5

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 39.0%

Weaknesses

2
  • Stock is trading at 14.8 times its book value
  • The company has delivered a poor sales growth of 8.67% over past five years.

Growth Rate

Revenue Growth
13.95% higher than 3Y
Net Income Growth
17.21% higher than 3Y
Cash Flow Change
65.64% lower than 3Y
ROE
4.64% lower than 3Y
ROCE
0.58% lower than 3Y
EBITDA Margin (Avg.)
4.36% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk medium

Divis Laboratories commands a market cap of ₹2,48,240 Cr and trades at a PE of 85.4x and 15.0x book value, reflecting premium valuations. The company is virtually debt-free with a 17% ROE in the last year, while TTM sales growth of 16% and profit growth of 29% signal an improving trajectory after a period of subdued top-line expansion averaging ~9% CAGR over five years.

Bull Case 7
  • Near debt-free balance sheet provides financial resilience and flexibility for capacity expansion without leverage risk
  • TTM profit growth of 29% significantly outpaces the 5-year compounded profit CAGR of 6%, indicating a strong earnings recovery cycle
  • TTM sales growth of 16% marks a notable acceleration versus the 5-year compounded sales CAGR of 9%
  • ROE of 17% last year is consistent with the 5-year average of 17% and 10-year average of 18%, reflecting durable return generation
  • Healthy dividend payout ratio of 39.0% demonstrates shareholder-friendly capital allocation despite being a growth-oriented pharma company
  • Stock CAGR of 57% over 1 year and 36% over 3 years reflects strong market re-rating and momentum
  • 10-year compounded sales CAGR of 11% and profit CAGR of 9% indicate a long track record of consistent growth through cycles
Bear Case 7
  • PE of 85.4x is significantly elevated relative to broader market and pharma sector averages, leaving limited margin of safety
  • Price-to-book of 15.0x is extremely rich, implying the stock prices in many years of future growth already
  • 5-year compounded sales growth of only 9% is modest for a stock commanding an 85x earnings multiple
  • 5-year compounded profit CAGR of just 6% suggests earnings growth has historically lagged the valuation premium
  • Dividend yield of 0.32% offers negligible income return, meaning investor returns depend almost entirely on capital appreciation
  • 3-year ROE of 15% is lower than the 10-year average of 18%, suggesting some compression in capital efficiency
  • The sharp 57% one-year stock CAGR raises the risk that near-term positive developments are already priced in at current levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 15d ago
Neutral 2
  • Q1 FY27 earnings call uploaded Aug 1

    Divis Labs uploaded the audio recording of its Q1 FY27 earnings conference call held on August 01, 2026, to its website for investor access.

  • Two senior VPs retire Jul 31

    L. Ramesh Babu and D. Madhu Babu retired as Senior Management Personnel effective July 31, 2026, disclosed under SEBI LODR Regulation 30.

TL;DR: A quiet news cycle for Divis Laboratories with only routine corporate disclosures — an earnings call upload and two senior VP retirements. No material positive or negative catalysts emerged. Investors should watch the Q1 FY27 earnings details for forward guidance on revenue and margin trajectory.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,778
1,909
1,855
2,303
2,118
2,338
2,319
2,585
2,410
2,715
2,604
2,831
3,080
Expenses
1,274
1,430
1,366
1,572
1,496
1,622
1,576
1,699
1,681
1,827
1,714
1,897
1,825
Operating Profit
504
479
489
731
622
716
743
886
729
888
890
934
1,255
OPM %
28%
25%
26%
32%
29%
31%
32%
34%
30%
33%
34%
33%
41%
Other Income
81
86
95
79
79
106
82
86
119
145
14
155
64
Interest
0
1
0
2
0
1
0
1
3
8
6
6
6
Depreciation
93
95
95
95
97
99
99
107
112
113
118
120
133
PBT
492
469
489
713
604
722
726
864
733
912
780
963
1,180
Tax %
28%
26%
27%
25%
29%
29%
19%
23%
26%
24%
25%
22%
24%
Net Profit
356
348
358
538
430
510
589
662
545
689
583
751
902
EPS in Rs
13.41
13.11
13.49
20.27
16.2
19.21
22.19
24.94
20.53
25.95
21.96
28.29
33.98
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,115
3,776
4,064
3,891
4,946
5,394
6,969
8,960
7,768
7,845
9,360
10,560
11,230
Expenses
1,942
2,354
2,615
2,622
3,072
3,568
4,102
5,075
5,397
5,635
6,387
7,118
7,263
Operating Profit
1,173
1,423
1,450
1,269
1,874
1,826
2,867
3,885
2,370
2,210
2,973
3,442
3,967
OPM %
38%
38%
36%
33%
38%
34%
41%
43%
31%
28%
32%
33%
35%
Other Income
38
93
72
107
154
186
57
112
344
335
348
433
378
Interest
3
5
3
2
5
7
2
2
2
4
3
24
26
Depreciation
136
118
123
142
169
186
256
312
343
378
402
463
484
PBT
1,072
1,393
1,395
1,231
1,855
1,819
2,666
3,684
2,369
2,163
2,916
3,388
3,835
Tax %
21%
19%
24%
29%
27%
24%
26%
20%
23%
26%
25%
24%
—
Net Profit
852
1,126
1,060
877
1,353
1,377
1,984
2,960
1,823
1,600
2,191
2,568
2,925
EPS in Rs
32.07
42.41
39.95
33.04
50.96
51.85
74.75
112
68.69
60.27
82.53
96.73
110
Div. Payout %
31%
24%
25%
30%
31%
31%
27%
27%
44%
50%
36%
31%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
27
53
53
53
53
53
53
53
53
53
53
53
Reserves
3,469
4,240
5,304
5,872
6,904
7,257
9,242
11,675
12,714
13,518
14,916
16,708
Borrowings
27
42
36
63
106
39
5
4
3
3
4
7
Other Liabilities
883
562
762
797
973
1,183
1,471
1,628
1,654
1,886
1,948
3,251
Total Liabilities
4,405
4,898
6,155
6,785
8,036
8,531
10,771
13,360
14,425
15,460
16,921
20,019
Fixed Assets
1,309
1,439
1,559
1,996
2,088
2,782
3,704
4,325
4,723
4,739
5,442
6,528
CWIP
218
264
444
120
492
920
711
470
212
778
1,022
2,113
Investments
733
803
1,631
1,889
1,946
971
0
72
77
82
65
69
Other Assets
2,145
2,392
2,521
2,780
3,511
3,858
6,356
8,493
9,413
9,861
10,392
11,309
Total Assets
4,405
4,898
6,155
6,785
8,036
8,531
10,771
13,360
14,425
15,460
16,921
20,019
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
826
1,038
1,150
776
954
1,216
1,947
1,912
2,460
1,261
1,653
2,738
Investing
-521
-406
-1,140
-478
-685
-83
75
-2,195
-2,708
-269
-804
-2,219
Financing
-303
-631
2
-314
-246
-1,091
-35
-532
-797
-799
-799
-804
Net Cash Flow
3
0
13
-17
23
41
1,987
-816
-1,045
193
50
-285
Free Cash Flow
519
642
774
502
221
33
1,037
1,199
1,987
258
215
221
CFO/OP
88
91
100
82
77
91
90
66
124
74
83
105
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
87
85
81
95
86
96
88
99
84
100
106
103
Inventory Days
350
293
307
314
347
316
329
341
352
364
311
346
Days Payable
68
56
104
96
96
100
117
96
89
94
88
106
Cash Conversion Cycle
368
322
284
313
336
312
300
344
347
370
330
343
Working Capital Days
140
158
147
176
169
180
152
177
188
206
192
195
ROCE %
33%
36%
29%
22%
29%
25%
32%
35%
19%
16%
20%
22%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Divis Laboratories insights

68 extracted metrics + investor summaries across FY06–FY27.

Log in — free

Shareholding Pattern

Others2.13%Promot.51.88%Public6.41%DIIs19.38%FIIs20.20%As ofJun 2026

Documents

Frequently Asked Questions about Divis Laboratories

What does Divis Laboratories Ltd do?
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
Where is Divis Laboratories Ltd (DIVISLAB) listed?
Divis Laboratories Ltd trades as DIVISLAB on the NSE and under code 532488 on the BSE.
Which sector does Divis Laboratories Ltd belong to?
Divis Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Divis Laboratories Ltd?
Divis Laboratories Ltd has a market capitalisation of ₹2,48,240 Cr, which places it in the Large Cap band.
What is the PE ratio of Divis Laboratories Ltd?
Divis Laboratories Ltd trades at a PE ratio of 84.61, on earnings per share of ₹63.06, against a book value of ₹631.38 per share.
What is the 52-week high and low of Divis Laboratories Ltd?
Over the last 52 weeks Divis Laboratories Ltd has traded between ₹5,636.5 and ₹9,615.
Does Divis Laboratories Ltd pay dividends?
Divis Laboratories Ltd has a dividend yield of 0.32%.
What is the Return on Equity (ROE) of Divis Laboratories Ltd?
Divis Laboratories Ltd reported a return on equity of 15.32%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Website divislabs.com
CEO Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Employees 10,542
Listed 2003-03-12
Face Value ₹ 2
Issued Size 26,54,68,580

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/DIVISLAB.md for Divis Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List